iBio Inc. (IBIO)
iBio Statistics
Share Statistics
iBio has 10.07M shares outstanding. The number of shares has increased by 14.51% in one year.
| Shares Outstanding | 10.07M |
| Shares Change (YoY) | 14.51% |
| Shares Change (QoQ) | 7.93% |
| Owned by Institutions (%) | 0.08% |
| Shares Floating | 8.6M |
| Failed to Deliver (FTD) Shares | 86 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.17M, so 11.87% of the outstanding shares have been sold short.
| Short Interest | 1.17M |
| Short % of Shares Out | 11.87% |
| Short % of Float | 11.89% |
| Short Ratio (days to cover) | 2.59 |
Valuation Ratios
The PE ratio is -0.31 and the forward PE ratio is -0.61. iBio's PEG ratio is 0.
| PE Ratio | -0.31 |
| Forward PE | -0.61 |
| PS Ratio | 34.22 |
| Forward PS | 84.5 |
| PB Ratio | 0.36 |
| P/FCF Ratio | -0.41 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for iBio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.21.
| Current Ratio | 4.08 |
| Quick Ratio | 4.08 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | -0.32 |
| Debt / FCF | -0.24 |
| Interest Coverage | -96.71 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $14.06K |
| Profits Per Employee | $-1.56M |
| Employee Count | 16 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -48.3% in the last 52 weeks. The beta is 1.02, so iBio's price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | -48.3% |
| 50-Day Moving Average | 3.59 |
| 200-Day Moving Average | 2.71 |
| Relative Strength Index (RSI) | 23.93 |
| Average Volume (20 Days) | 787.19K |
Income Statement
In the last 12 months, iBio had revenue of 225K and earned -24.91M in profits. Earnings per share was -6.5.
| Revenue | 225K |
| Gross Profit | 225K |
| Operating Income | -16.63M |
| Net Income | -24.91M |
| EBITDA | -14.02M |
| EBIT | -15.27M |
| Earnings Per Share (EPS) | -6.5 |
Balance Sheet
The company has 14.21M in cash and 4.46M in debt, giving a net cash position of 9.75M.
| Cash & Cash Equivalents | 14.21M |
| Total Debt | 4.46M |
| Net Cash | 9.75M |
| Retained Earnings | -313.85M |
| Total Assets | 21.7M |
| Working Capital | 3.58M |
Cash Flow
In the last 12 months, operating cash flow was -18.55M and capital expenditures -210K, giving a free cash flow of -18.76M.
| Operating Cash Flow | -18.55M |
| Capital Expenditures | -210K |
| Free Cash Flow | -18.76M |
| FCF Per Share | -4.9 |
Margins
Gross margin is 100%, with operating and profit margins of -7392.89% and -11069.78%.
| Gross Margin | 100% |
| Operating Margin | -7392.89% |
| Pretax Margin | -6863.56% |
| Profit Margin | -11069.78% |
| EBITDA Margin | -6231.56% |
| EBIT Margin | -7392.89% |
| FCF Margin | -8339.56% |
Dividends & Yields
IBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IBIO is $5, which is 449.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 449.5% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Nov 29, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Nov 29, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -22.05 |
| Piotroski F-Score | 4 |